Glucocorticoid regulation of hepatic TNF production following cecal ligation and puncture sepsis

Shock

Volumn 8, Issue 2, 1997, Pages 141-145

  Zawacki, Jeffrey K ^a   Hunt, Julia L ^b   Gamelli, Richard L ^a   Filkins, James P ^a,b  

^a Department of Surgery ^*  (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; TUMOR NECROSIS FACTOR ALPHA;

ADRENALECTOMY; ANIMAL; ARTICLE; INTESTINE; LIVER; MALE; METABOLISM; PATHOLOGY; RAT; SEPSIS;

ADRENALECTOMY; ANIMALS; GLUCOCORTICOIDS; INTESTINES; LIVER; MALE; RATS; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031205447     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199708000-00014     Document Type: Article

References (39)

1. Hinshaw LB, Beller BK, Chang ACK, et al: Corticosteroid/antibiotic treatment of adrenalectomized dogs challenged with lethal E. coli. Circ. Shock 16:265-277, 1985.
2. McCallum RE, Stith RD: Endotoxin-induced inhibition of steroid binding by mouse liver cytosol. Circ. Shock 9:357-367, 1982.
3. Hinshaw LB, Brake CM, Emerson TE Jr, Jordan MM, Masucci FD: Participation of sympathoadrenal system in endotoxic shock. Am J Physiol 207:925-930, 1964.
4. Karck U, Peters T, Decker K: The release of tumor necrosis factor from endotoxin stimulated rat kupffer cells is regulated by prostaglandin E2 and dexamethasone. J Hepatology 7:352-361, 1988.
5. Chensue SW, Terebuh PD, Remick DG, Scales WE, Kunkel SL: In vivo biologic and immunohistochemical analysis of interleukin-1α, β and tumor necrosis factor during experimental endotoxemia. Am J Pathology 138:395-402, 1991.
6. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A: Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance. Science 232:977-980, 1986.
7. Zuckerman SH, Shellaas J, Butler LD: Differential regulation of lipopolysaccharide induced interleukin-1 and tumor necrosis factor synthesis: Effects of endogenous and exogenous glucocorticoids and the role of the pituitary-adrenal axis. Eur J Immunology 19:301-305, 1989.
8. Evans GF, Snyder YM, Butler SH, Zuckerman SH: Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models. Circ. Shock 29:279-290, 1989.
9. Hesse DG, Tracey KJ, Fong Y, et al: Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 166:147-153, 1988.
10. Michie HR, Manogue KR, Spriggs DR, et al: Detection of circulating tumor necrosis factor after endotoxin administration. N EngI J Med 318: 1481-1486, 1988.
11. Hinshaw LB, Tekamp-Olsen P, Chang ACK, et al: Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF-alpha). Circ Shock 30:279-292, 1990.
12. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474, 1986.
13. Eskandari MK, Bolgos G, Miller L, Nguyen DT, DeForge LE, Remick DG: Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunology 148: 2724-2730, 1992.
14. Ayala A, Perrin MM, Kisala JM, Ertel W, Chaudry IH: Polymicrobial sepsis selectively activates peritoneal but not alveolar macrophages to release inflammatory mediators (interleukins-1 and -6 and tumor necrosis factor). Circ. Shock 36:191-199, 1992.
15. Hajiminas DJ, McMasters KM, Peyton JC, Cheadle WG: Tissue tumor necrosis factor mRNA expression following cecal ligation and puncture or intraperitoneal injection of endotoxin. J Surg Res 56:549-555, 1994.
16. Alexander HR, Sheppard BC, Jensen JC, et al: Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram negative sepsis. J Clin. Invest. 88:34-39, 1991.
17. McMasters KM, Payton JC, Hadjiminas DJ, Cheadle WG: Endotoxin and tumor necrosis factor do not cause mortality from cecal ligation and puncture. Cytokine 6:530-536, 1994.
18. Bagby GJ, Plessaia KJ, Wilson LA, Thompson JJ, Nelson S: Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J Infect. Dis. 163:83-88, 1991.
19. Wichterman KA, Baue AE, Chaudry IH: Sepsis and septic shock - a review of laboratory models and a proposal. J. Surg. Research 29:189-201, 1980.
20. McCallum RE, Lloyd SS, Hyde SR: Enhanced TNF response in endotoxic mice after treatment with glucocorticoid antagonist ru486. In Nowotny A, Spitzer JJ, Zeigler EJ (eds) Cellular and Molecular Aspects of Endotoxin Reactions. Elsevier Science Publishers B. V., 1990, pp 493-500.
21. Kumins NH, Hunt JL, Gamelli RL, Filkins JP: The perfused mouse liver produces TNF, IL-1, and IL-6 and endotoxin. In Surgical Forum Vol XLV, 1994, pp 59-62.
22. Kumins NH, Hunt JL, Gamelli RL, Filkins JP: Partial hepatectomy reduces the endotoxin induced peak circulating level of TNF in rats. Shock 1 (suppl):17-18, 1994.
23. Liao J, Keiser JA, Scales WE, Kunkel SL, Kluger MJ: Role of epinephrine in TNF and IL-6 production from the isolated perfused rat liver. Am J Physiol 268:R896-901, 1995.
24. Tran-Thi TA, Weinhold L, Weinstock C, Hoffmann R, Schulze-Specking A, Northoff H, Decker K: Production of tumor necrosis factor-alpha, interleukin-1, and interleukin-6 in the perfused rat liver. Eur Cyt Network 4:363-370, 1993.
25. Evans GF, Zuckerman SH: Glucocorticoid-dependent and -independent mechanisms invovlved in lipopolysaccharide tolerance. Eur J Immunol 21:1973-1979, 1991.
26. Rothwell PM, Udwadia, ZF, Lawler PG: Cortisol response to corticotropin and survival in septic shock. Lancet 337:582-583, 1991.
27. Siegel LM, Grinspoon SK, Garvey GJ, Bilezikian JP: Sepsis and adrenal function. Trends Endocrinol Med 5:324-328, 1994.
28. Sibbald WJ, Short A, Cohen MP, Wilson RF: Variations in adrenocortical responsiveness during severe bacterial infections. Ann Surg 186:29-33, 1977.
29. The Veterans Administration Systemic Sepsis Cooperative Group: Effect of high dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317:659-665, 1987.
30. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA, the Methylprednisolone Severe Sepsis Study Group: A controlled clinical trail of high dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653-658, 1987.
31. Schein RMH, Sprung CZ, Marcial E, Napolitano L, Chernow B: Plasma cortisol levels in septic shock. Crit Care Med 18:259-263, 1990.
32. Finlay WEI, McKee JI, Serum cortisol levels on severely stressed patients. Lancet 1:414-415: 1982.
33. Remick DC, Stricter RM, Lynch JP III, Nguyen D, Eskandari M, Kunkel SL: In vivo dynamics of murine tumor necrosis factor-alpha gene expression. Lab Invest 60:766-771, 1989.
34. Barber AE, Coyle SM, Marano MA, et al: Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 150:1999-2006, 1993.
35. Gonzalez JC, Johnson DC, Morrison DC, Freundenberg MA, Galanos C, Silverstein R: Endogenous and exogenous glucocorticoids have different roles in modulating endotoxinlethality in D-galactosamine-sensitized mice. Infect Immun 61:970-974, 1993.
36. Hinshaw LB, Beller BK, Archer LT, Flournoy DJ, White GL, Phillips RW: Recovery from lethal escherichia coli shock in dogs. Surg Gynecol Obstet 149:5435-553, 1979.
37. Hinshaw LB, Archer LT, Beller-Todd BK, Benjamin B, Flournoy DJ, Passey R: Survival of primates in lethal septic shock following delayed treatment with steroid. Circ Shock 8:291-300, 1981.
38. Zawacki JK, Hunt JL, Gamelli RL, Filkins, JP: Tyrosine kinase inhibition blocks hepatic TNF and IL-1 production during cecal ligation and puncture sepsis and improves early survival. In Surgical Forum Vol XLVII, 1996, pp 81-84.
39. Chelmicka-Schorr E, Kwasniewski BE, Czlonkowska A: Sympathetic nervous system and macrophage function. Ann NY Acad Sci 650:40-45, 1992.